Navigation Links
Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
Date:1/28/2009

ubt.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing clinical diagnostic laboratory tests and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a protein-based clinical laboratory test to identify patients with Hp2-2 diabetes. Tests which identify patients with Hp2-2 diabetes may be useful in identifying diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

For more information, please visit the Company's Web site at www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, the Company's ability to obtain sufficient financing to allow it to continue operations, future clinical development of Synvista Therapeutics' diagnostic tests and product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2007. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligati
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
3. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
4. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
5. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
6. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
7. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
8. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
9. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
10. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Texas , Aug. 21, 2014  Vermillion, Inc. ... focused on gynecologic cancers and women,s health, has appointed ... Sales and Managed Markets. Ms. Bauzon has ... and expanding payer coverage for laboratory services companies. She ... recently with PerkinElmer, Inc., where she held the position ...
(Date:8/21/2014)...  eRelevance Corporation ( www.erelevancecorp.com ), a progressive ... has completed integration with Nextech, a popular Electronic ... Dermatology practices. "Integration allows our service ... using Nextech," stated Bob Fabbio , co-founder ... the EMR we are able to automatically target ...
(Date:8/21/2014)... , Aug. 21, 2014  Publicis Groupe ... Hartley , Managing Partner and Healthcare Industry Group Leader, ... 100, which recognizes the most inspiring people in the ... leaders in research and development, marketing, technology, creativity, strategy ... in 2006 as a partner in its leading Rosetta ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Shannon Hartley Shines in PharmaVOICE 100 2
... Watson Pharmaceuticals, Inc. (NYSE: WPI ... Inc., filed an Abbreviated New Drug Application (ANDA) ... seeking approval to market Norethindrone Acetate/Ethinyl Estradiol and Ethinyl ... mg and 75 mg. Watson,s ANDA product is ...
... 2012 UCB, Inc., a leading biopharmaceutical company dedicated ... central nervous system and immunological disorders, is marking Digestive ... its commitment to improving the lives of patients with ... year,s DDW meeting. "DDW is an ...
Cached Medicine Technology:Watson Confirms Lo Loestrin® Fe Patent Challenge 2Watson Confirms Lo Loestrin® Fe Patent Challenge 3UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 2UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 3UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 4
(Date:8/21/2014)... The W. Montague Cobb/ NMA Health ... voice in the elimination of health disparities, honored ... 112th National Medical Association’s (NMA) Annual Convention and ... Ruffin, Ph.D, former Director of the National Institute ... career and innovations have had a significant impact ...
(Date:8/21/2014)... Rockville, MD (PRWEB) August 21, 2014 ... Pediatrics reported a 63% increase in disability associated with ... along with a more than 15% increase in disability ... of early intervention for rising numbers of children who ... Speech-Language-Hearing Association (ASHA). , On a broader ...
(Date:8/21/2014)... To sexually objectify a woman is to focus on ... sexual pleasure rather than viewing her as a complete ... long been considered a problem in the media, how ... in Psychology of Women Quarterly , a SAGE ... body is related to higher incidents of sexual pressure ...
(Date:8/21/2014)... Aug. 21, 2014 Researchers in the United ... cataracts can quickly and accurately diagnose a number of ... study published online today in Ophthalmology ... Using a single test, doctors were able to ... their mutations reducing the time and money spent on ...
(Date:8/21/2014)... New York (PRWEB) August 21, 2014 ... blood thinner caused patients to suffer uncontrollable internal bleeding ... courts, Bernstein Liebhard LLP reports. According to court documents, ... in U.S. District Court, Easter District of New York ... due to a bleeding event that was allegedly caused ...
Breaking Medicine News(10 mins):Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:Objectification in romantic relationships related to sexual pressure and coercion 2Health News:New DNA test for diagnosing diseases linked to childhood blindness 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4
... , FARMINGDALE, N.Y., Sept. 2 Misonix, ... invasive ultrasonic medical device technology, which in Europe is used ... health conditions, today announced the restructuring and expansion of its ... created; one for sales and service of the Sonablate(R) 500 ...
... COLO Research published in the September 2009 issue of ... an individual,s quality of life prior to treatment can help ... cell lung cancer (NSCLC). For those with advanced stage ... months, with approximately one-third of patients surviving past the one ...
... models to comb through thousands of injury reports in ... automatically classify them based on specific words or phrases. ... causes of injuries so that efforts could be directed ... Mark Lehto, an associate professor in Purdue University,s School ...
... ... in Chicago, IL USA offers two for one deal on summits. Also book your ... ... three weeks until Biopolymers Symposium 2009 conference and exhibit, taking place at the Embassy Suites ...
... , , , ... NBIX ) announced today that Kevin Gorman, President and Chief ... Partners Healthcare Conference in Boston. , , The ... Time (ET)/6:45 a.m. Pacific Time (PT). The presentation will be simultaneously ...
... occur before 65, study finds, many younger patients not ... Stroke could be affecting Americans earlier in life than ... no longer an affliction of old age," said lead ... and neurology and investigator for the Cognitive Rehabilitation Research ...
Cached Medicine News:Health News:Misonix Restructures and Expands Sales Organization in Europe 2Health News:Misonix Restructures and Expands Sales Organization in Europe 3Health News:Misonix Restructures and Expands Sales Organization in Europe 4Health News:New computer models aim to classify, help reduce injury accidents 2Health News:Biopolymers Symposium 2009 Offers Two for One Deal: Attend Retailers Scorecard Seminar and Attend the EcoLabeling Summit Free 2Health News:Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2Health News:Stroke May Be Striking at a Younger Age 2Health News:Stroke May Be Striking at a Younger Age 3
... with a 10-foot, kink-resistant cord for easier, ... electrosurgical pencils are the only product on ... non-stick tips allowing surgeons to make cleaner ... CLEAN PTFE coating is proven to last ...
... it maximizes use by allowing two ... while the third lamp is reserved ... in mind, it includes universal turrets ... excellent choice for hospital operating rooms ...
... The patented Applied Fiberoptics Gemini surgical headlight ... The headlight is durable and ultra-low-profile and ... closely without the annoying "rams effect." The ... nylon, is designed to sit low on ...
... use of some micro vascular clamps can ... With use, Stainless steel changes its elasticity, ... that pressures above 30g/mm2 may be associated ... from titanium which does not change its ...
Medicine Products: